REGULATORY AGENCY ACTION
At its December meeting, the Board
vote for President resulted in a tie between
John Anthony, OD, and Pamela Miller,
OD, JD. Because of the tie, existing president Thomas Nagy, OD, will continue to
serve as president until a new vote is taken
at the March meeting. The committee
chairs will also remain the same until
March, as they are selected by the President.
*

FUTURE MEETINGS
March 11-12 in Long Beach.
May 19-20 in San Diego (tentative).

BOARD OF PHARMACY
Executive Officer: PatriciaHarris
(916) 445-5014
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ursuant to Business and Professions
Code section 4000 et seq., the Board
of Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manufacturers, wholesalers, and sellers of hypodermic needles. It regulates all sales of
dangerous drugs, controlled substances,
and poisons. The Board is authorized to
adopt regulations, which are codified in
Division 17, Title 16 of the California
Code of Regulations (CCR). To enforce its
regulations, the Board employs full-time
inspectors who investigate complaints received by the Board. Investigations may
be conducted openly or covertly as the
situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized by
law to suspend or revoke licenses or permits for a variety of reasons, including
professional misconduct and any acts substantially related to the practice of pharmacy.
The Board consists of ten members,
three of whom are nonlicensees. The remaining members are pharmacists, five of
whom must be active practitioners. All are
appointed for four-year terms.
At the Board's October 6 meeting,
President Raffi Simonian introduced new
Board members Holly Ann Strom and
Gary Dreyfus, appointed by Governor
Wilson on August 19. Strom is drug education coordinator for Kaiser Permanente
in West Los Angeles; Dreyfus is president
of Moulton Plaza Pharmacy in Laguna
Hills, and has fourteen years of experience
as a self-employed pharmacist.

* MAJOR PROJECTS
Board Proposes Regulation on Furnishing to Home Health Agencies. On
December 10, the Board published notice
of its intent to adopt new section 1751.11,
Talifnrnia

Title 16 of the CCR, to establish a list of
dangerous drugs which may be furnished
by a pharmacist to a licensed home health
agency and stored in transportable, tamper-proof, sealed storage containers.
t13:4 CRLR 82] According to the Board,
the drugs on the list are used in parenteral
therapy and do not include controlled substances; the sealed storage container
would be issued by a licensed pharmacy
to a home health agency registered nurse,
who could bring a portable container with
him/her during home care visits to patients. Under the proposed regulation,
drugs could be furnished by the home
health agency registered nurse from the
portable container to patients pursuant to
a prescription or an oral order for emergency treatment or adjustment of parenteral drug therapy; specific administration
protocols would be established regarding
the furnishing of any dangerous drug from
the portable container by the registered
nurse.
Among other things, the regulation
would establish inventory and recordkeeping requirements for the pharmacy
that prepares the containers; require the
home health agency to keep additional
records regarding furnishing; set requirements for the home health agency regarding orally transmitted orders from licensed prescribers to the registered nurse
to authorize furnishing drugs from the
containers; and establish storage requirements to assure that the container is not
exposed to excessive heat or cold which
could damage the contents.
At this writing, the Board is scheduled
to conduct a public hearing on the proposed adoption of section 1751.11 on January 26 in Sacramento.
Citation and Fine Program. On October 6, the Board held a public hearing on
the proposed adoption of new Article 9.5,
commencing with section 1775, Title 16
of the CCR; the new article would implement Business and Professions Code section 125.9 and authorize the Board's Executive Officer to issue citations and fines
for specified violations of law. [13:4
CRLR 79] At the hearing, several individuals and representatives of professional
groups and private pharmacies expressed
opposition to the proposed regulations,
claiming that they fail to provide adequate
due process; delegate powers which only
the Board should exercise; create an adversarial atmosphere between pharmacists and the Board; make it difficult to
determine who to fine (employee or supervisor); lack a statistical showing of need;
provide too broad a range of discretionary
fines; cost too much; do not affect major
violators; present too large a potential to
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clog the system with appeals; preclude
further use of facts if stronger disciplinary
action is needed; and could potentially be
used against a licensee in a civil action.
The Board received other comments in
support of the proposal from individuals
who contended that many of the above
issues could be addressed through modified regulatory language; the legislature
enacted the citation and fine program to
enable agencies to deal with mid-level
problems that do not justify the filing of
an accusation and, although the specific
facts could not be used for further discipline, further action would not be contemplated unless further evidence becomes
available; under the proposed regulations,
licensees would continue to have the full
Administrative Procedure Act appeal process available; the Board could consider
an informal appeal process to the Executive Officer; and the program does not
include an admission of guilt on the
pharmacist's part. Retired Board Supervising Inspector Ken Sain noted that the
citation and fine mechanism is an excellent tool for stopping unlicensed activity,
which often goes unaddressed by district
attorney's offices and other law enforcement agencies which must handle higherpriority matters.
Following discussion, the Board unanimously deferred action on the proposed
regulations and referred the matter to its
Enforcement Committee for further review; specifically, the Board directed the
Enforcement Committee to closely reexamine the proposed regulations, suggest
alternative ways to pursue a citation and
fine program, and-if appropriate-develop the necessary language. The Committee is expected to present its findings
to the Board at a future meeting.
Fee Increases Postponed. Last August, the Board published notice of its
intent to amend sections 1749 and 1793.5,
Title 16 of the CCR, to increase specified
license fees; according to the Board, the
fee increases are necessary to restore the
Board's reserve fund and maintain it at a
prudent level to enable it to conduct ongoing operations. [13:4 CRLR 79] At the
Board's October 6 meeting, Executive Officer Patricia Harris reported new budget
information which indicates that a fee increase will not be needed until July 1995,
and that an increase in fees to the maximum allowed by statute would result in
too high a surplus. Although Department
of Consumer Affairs staff counsel Robert
Miller noted that the Board could consider
adopting the changes with a delayed effective date, the Board unanimously voted to
indefinitely table the proposed fee increases.
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Rulemaking Update. The following
is a status update on other Board rulemaking proposals discussed in detail in previous issues of the Reporter:
- In July 1993, the Board adopted a
proposed amendment to section 1732.3,
Title 16 of the CCR, regarding the duration of its approval of continuing education (CE) courses. Specifically, the proposed change would provide that a recognized Board provider's coursework shall
be valid for three years following the initial Board approval; currently, such coursework is valid for two years following initial
Board approval. This change would conform the Board's CE course validity period
to that used by the American Council on
Pharmaceutical Education. [13:4 CRLR 79;
13:2&3 CRLR 101] This change still awaits
review and approval by the Office of Administrative Law.
* Also in July 1993, the Board conducted a public hearing on its proposal to
amend section 1717(a), Title 16 of the
CCR, which provides that-with specified exceptions-no medication shall be
dispensed on prescription except in a new
container which conforms with standards
established in the official compendia; the
Board's proposed amendment would
allow pharmacists to refill a prescription
for non-liquid oral products in a clean,
safe container previously provided to the
same patient for the same drug, provided
a new label is securely attached to the
container. During the hearing, staff noted
a comment submitted by the U.S. Consumer Product Safety Commission (CPSC)
stating that federal law does not allow the
reuse of child-resistant packaging or containers. Following discussion, the Board
agreed to defer the regulation until its October meeting pending further research regarding the limitation of federal law and
regulations. However, the Board modified
the proposed language to provide that a
pharmacy may, at the request of the patient
or his/her agent, reuse prescription containers under the circumstances described
above, provided the container is not a
child-resistant container; the Board directed staff to release the modified language for an additional fifteen-day public
comment period. [13:4 CRLR 80; 13:2&3
CRLR 101]
At the Board's October 6 meeting, Executive Officer Patricia Harris reported
that staff had asked CPSC for clarification
of its position regarding the proposed regulations; in response, CPSC stated that
any rule allowing the reuse of child-resistant containers would conflict with 16
C.F.R. Part 1700.15(a), and that the prohibition against the reuse of child-resistant
containers makes no exceptions, even if
F4

requested by the patient. According to
CPSC Western Region Senior Compliance Officer Albert Limberg, "[i]ogic dictates that neither the pharmacist nor the
patient would be in any reasonable position to establish the effectiveness of the
returned container, the number of reuses it
has been subjected to or its remaining
useful life." Further, Limberg counseled
the Board to "forget the whole idea," contending that if environmental and recycling issues are the principal concern of the
Board, a cost-benefit analysis indicates
that the cost would be borne mainly "by
the poisoning victim should a reuse rule
be written." The California Employee
Pharmacist Association voiced similar
concerns about the safety of reused containers. Following discussion, the Board
unanimously voted to indefinitely table
the proposed regulatory action.
Future Rulemaking. At its October 6
meeting, the Board agreed to pursue
rulemaking to modify section 1724, Title
16 of the CCR, regarding the procedure
for scoring and grading the pharmacist
licensure examination. The Board will
propose to repeal section 1724(b), which
currently provides that a candidate achieving a score of less than 75 on one section
of the exam may retake only that one
section at the next scheduled exam; if a
candidate exercises this option and fails to
achieve a score of 75 or more, the candidate must take the entire examination
upon the next application. Under the modified proposal, staff will grade the multiple-choice portion of the exam first; if a
candidate fails that section, staff will not
grade his/her essay exam, thus eliminating
the need to grade approximately 30% of
the essays submitted for each exam administration. At this writing, the proposal
has not been published in the California
Regulatory Notice Register.

U

LEGISLATION
SB 1048 (Watson), as introduced
March 5, would establish the Clean Needle and Syringe Exchange Pilot Project,
and authorize pharmacists, physicians,
and certain other persons to furnish hypodermic needles and syringes without a prescription or permit as prescribed through
the pilot project. Governor Wilson vetoed
a similar bill, AB 260 (W. Brown), last
October. [S. Floor]
AB 667 (Boland). The Pharmacy Law
regulates the use, sale, and furnishing of
dangerous drugs and devices, as defined;
the law prohibits a person from furnishing
any dangerous device, except upon the
prescription of a physician, dentist, podiatrist, or veterinarian. However, existing
law provides that this prohibition does not

apply to the furnishing of any dangerous
device by a manufacturer, wholesaler, or
pharmacy to each other or to a physician,
dentist, podiatrist, veterinarian, or physical therapist acting within the scope of
his/her license under sales and purchase
records that correctly give the date, the
names and addresses of the supplier and
the buyer, the device, and its quantity. As
amended March 29, this bill would provide that the prohibition also does not
apply to the furnishing of any dangerous
device by a manufacturer, wholesaler, or
pharmacy to a chiropractor acting within
the scope of his/her license.
Existing law authorizes a medical device retailer to dispense, furnish, transfer,
or sell a dangerous device only to another
medical device retailer, a pharmacy, a licensed physician, a licensed health care
facility, a licensed physical therapist, or a
patient or his/her personal representative.
This bill would additionally authorize a
medical device retailer to dispense, furnish, transfer, or sell a dangerous device
to a licensed chiropractor. [A. Health]
SB 849 (Bergeson). Under the Pharmacy Law, a "hospital pharmacy" means
and includes a pharmacy licensed by the
Board of Pharmacy located within any
hospital, institution, or establishment that
maintains and operates organized inpatient facilities for the diagnosis, care, and
treatment of human illnesses in accordance with certain requirements. Existing
law requires the Department of Health
Services to issue a single consolidated license to a general acute care hospital that
meets certain requirements. As amended
June 1, this bill would instead define a
"hospital pharmacy" to mean a pharmacy
licensed by the Board and located either
within the physical plant of a general acute
care hospital, as defined, acute psychiatric
hospital, as defined, or special hospital, as
defined, or outside of the hospital in another physical plant that is regulated under
the hospital's single consolidated license,
in accordance with certain requirements.
[A. Health]
AB 1807 (Bronshvag), as amended
September 8, would provide that, notwithstanding specified security measures, a
medical device retailer could establish a
locked facility for furnishing dangerous
devices in emergencies or after working
hours, and would allow the Board to authorize revisions in the security measures
pertaining to the delivery of dangerous
devices from locked storage to patients.
Existing law defines the term "prescription" for the purposes of existing law
relating to licensure of pharmacists, regulation of pharmacies, and regulation of
controlled substances. This bill would re-
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vise the definition of the term prescription,
for those purposes, to also include electronically transmitted prescriptions, as defined. [13:2&3 CRLR 100-01]
This bill would also provide that any
order for a Schedule II controlled substance in a licensed skilled nursing facility, intermediate health care facility, or a
licensed home health agency providing
hospice care may be dispensed upon an
oral or electronically transmitted prescription; and would require these facilities to
forward to the dispensing pharmacist a
copy of any signed telephone order, chart
order, or related documentation substantiating each oral prescription transaction.
[A. Inactive File]
AB 2020 (Isenberg), as amended June
17, would, among other things, authorize
optometrists to use, prescribe, and dispense specified pharmaceutical compounds to a patient; provide that any use,
prescribing, or dispensing of a pharmaceutical agent to a patient by an optometrist pursuant to these provisions is limited
to that which is incidental to the practice
of optometry; specify that dispensing by
the optometrist to a patient be without
charge; and make it a misdemeanor for
any person licensed as an optometrist to
refer a patient to a pharmacy that is owned
by that licensee or in which the licensee
has proprietary interest. [S. B&P]

*

LITIGATION

In Huggins v. Longs Drug Stores California, Inc., 6 Cal. 4th 124 (Nov. 18,
1993), the California Supreme Court reversed the Fifth District Court of Appeal's
ruling that a pharmacist's provision of incorrect dosage amounts for a prescription

which the pharmacist knew or should have
known would be administered to an infant
by the infant's parents constitutes negligent action by the pharmacist directed at
the parent caregivers, which may allow
the parent caregivers to state a claim as
direct victims and recover damages for
negligent infliction of emotional distress.
[13:4 CRLR 81-82; 13:1 CRLR 63]
In reversing the Fifth District's decision, the Supreme Court acknowledged
that it has allowed recovery for parental
emotional distress resulting from professional mistreatment of a child by health
care providers who were concurrently
treating the parents as patients. However,
where the plaintiff (here, the parent) is not
the patient of the defendant caregiver
(here, the pharmacist), courts have not
extended the direct victim cause of action
to emotional distress which is derived
solely from a reaction to another's injury.
The court found that the duty the Fifth
District's ruling would impose upon phar-

macists would inevitably enlarge the potential liability of practically all providers
of medical goods and services obtained by
parents solely for the treatment of their
children, or by other caregivers solely for
the treatment of dependent family members; according to the court, that expansion of potential liability "not only would
increase medical malpractice insurance
costs but also would tend to 'inject undesirable self-protective reservations' impairing the provision of optimal care to the
patient."
Justices Stanley Mosk and Joyce
Kennard wrote dissenting opinions critical of the majority decision. Mosk opined
that he "fail[s] to see how the imposition
of liability here would be any novelty; a
statutory duty to provide accurate instructions was breached and the persons to
whom the instructions were directed seek
compensation." Kennard contended that
"[i]t is difficult to imagine just what 'undesirable self-protective reservations' a
pharmacist under a duty to provide accurate instructions for the use of medicines
might have that would impair patient care
as a result of allowing parents to recover
in the circumstances of this case. Allowing
parents to recover against pharmacists as
direct victims when they have personally
administered medication causing serious
injury to their children would rationally
tend to assure that the pharmacist's legal
duty to consult with the patient or the
patient's agent is more, not less, effectively fulfilled" (emphasis original).
On October 27, the Second District
Court of Appeal upheld the trial court's
decision in Californiansfor Safe Prescriptions v. California State Board of
Pharmacy, 19 Cal. App. 4th 1136, finding
that the Board complied with the Administrative Procedure Act in promulgating
and adopting its pharmacy technician regulations which authorize the use of pharmacy technicians in nondiscretionary
tasks associated with dispensing drugs.
[13:4 CRLR 82; 13:1 CRLR 62]

U

RECENT MEETINGS

At its October meeting, the Board discussed the Drug Enforcement Agency's
(DEA) response to its request for clarification of 21 C.F.R. Part 1304.04, which
requires pharmacists to stamp a red "C" on
the hard copy of controlled substance prescriptions; recognizing the increasing
computerization of pharmacies, the Board
asked DEA to allow pharmacies to either
maintain a separate electronic file of
Schedule III-V controlled substances, or
maintain a separate physical file of Schedule III-V controlled substances, or mark
all Schedule III-V controlled substance
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prescriptions with a red "C." [13:4 CRLR

82] In its response, DEA offered two options for pharmacies: a pharmacy niay either keep controlled substance prescriptions physically separate from other prescriptions, or commingle these and other
prescriptions, in which case a red "C"
must be stamped on controlled substance
prescriptions. Existing DEA regulations
do not address the electronic maintenance
of prescriptions. Some Board members
opined that DEA's regulations seriously
affect computerization, and that computerization enhances enforcement efforts by
offering easier inspection capabilities.
The Board directed Deputy Attorney General William Marcus to write to DEA requesting reconsideration of the issue in
light of the increased use of electronic
prescription maintenance.
Also on October 6, the Board discussed whether to propose legislation
which would require one Board member
to be a pharmacist who dispenses prescriptions in the outpatient or community pharmacy setting. Instead of pursuing the
change at this time, the Board directed
staff to draft a letter to the Governor's
Appointment Secretary expressing the
Board's desire to have members who are
actively practicing in the community setting.
Also at its October meeting, the Board
discussed the response from Department
of Health Services (DHS) to its letter requesting DHS to permit an increase in the
number of different oral drugs which may
be stored in the emergency drug supply of
a licensed skilled nursing facility. Currently, DHS permits six drugs and allows
flexibility for up to twelve drugs; on the
recommendation of its Long-Term Care
Committee, the Board requested that DHS
allow flexibility for up to 24 drugs. Board
President Raffi Simonian reported that
DHS declined the Board's request, but
agreed to consider further requests on a
case-by-case basis. A representative from
the California Pharmacists Association
(CPhA) inquired whether the twelve drugs
could vary from nursing station to nursing
station within the facility. Because the
Board understands its role on this issue as
advisory-with DHS approving what actually goes into the kit, the Board asked
CPhA to seek this clarification from DHS
and report back at the next Board meeting
regarding DHS' response.

*

FUTURE MEETINGS
March 30-31 in Los Angeles.
May 25-26 in Sacramento.

